Form 4: Recursion Pharmaceuticals CFO Ben R. Taylor Reports Tax Withholding Transaction
SEC Form 4 Filing
Ben R. Taylor, CFO of Recursion Pharmaceuticals, reports a transaction involving the withholding of shares to cover tax obligations related to restricted stock units.
Summary
- On March 17, 2025, Ben R. Taylor, the Chief Financial Officer of Recursion Pharmaceuticals, reported a transaction on SEC Form 4.
- The transaction involved the withholding of 7,057 shares of Class A Common Stock at a price of $6.84 to satisfy tax withholding obligations related to the net settlement of restricted stock units.
- Following the transaction, Taylor directly owns 868,670 shares of Class A Common Stock.
- Taylor also holds various stock options to purchase Class A Common Stock at exercise prices ranging from $0.04 to $7.25, with expiration dates between 2030 and 2035.
- These options represent the right to buy a total of 1,274,462 shares.
- The reporting person has pre-arranged trading plans under Rule 10b5-1(c).
Sentiment
Score: 5
Explanation: This is a neutral disclosure of a routine transaction related to executive compensation and tax obligations.
Industry Context
This filing is a routine disclosure related to executive compensation and tax obligations, common in publicly traded companies.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it relates to tax obligations.
Key Dates
| Date | Description |
|---|---|
| 11/17/2021 | 25% of shares subject to one stock option award vest and become exercisable. |
| 04/03/2022 | 25% of shares subject to one stock option award vest and become exercisable. |
| 07/01/2022 | 25% of shares subject to one stock option award vest and become exercisable. |
| 01/02/2025 | 1/48th of the shares subject to one stock option award vests and become exercisable. |
| 03/01/2025 | 1/48th of the shares subject to one stock option award vests and become exercisable. |
| 03/17/2025 | Date of the reported transaction: withholding of shares for tax obligations. |
| 03/19/2025 | Date of signature for the Form 4 filing. |
| 04/02/2031 | Expiration date for one of the stock option awards. |
| 07/01/2031 | Expiration date for one of the stock option awards. |
| 11/26/2030 | Expiration date for one of the stock option awards. |
| 12/18/2034 | Expiration date for one of the stock option awards. |
| 02/03/2035 | Expiration date for one of the stock option awards. |
Keywords
Form 4, Beneficial Ownership, RXRX, Recursion Pharmaceuticals, Ben R. Taylor, CFO, Stock Options, Tax Withholding, Class A Common Stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.